244 related articles for article (PubMed ID: 26919982)
1. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
2. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Apr; 21(2):350-358. PubMed ID: 26370256
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
[TBL] [Abstract][Full Text] [Related]
5. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
[TBL] [Abstract][Full Text] [Related]
6. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
[TBL] [Abstract][Full Text] [Related]
7. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers.
Chiang SF; Huang CY; Ke TW; Chen TW; Lan YC; You YS; Chen WT; Chao KSC
Cancer Immunol Immunother; 2019 Feb; 68(2):283-296. PubMed ID: 30448924
[TBL] [Abstract][Full Text] [Related]
9. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J
Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115
[TBL] [Abstract][Full Text] [Related]
10. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
Shurell E; Singh AS; Crompton JG; Jensen S; Li Y; Dry S; Nelson S; Chmielowski B; Bernthal N; Federman N; Tumeh P; Eilber FC
Oncotarget; 2016 Sep; 7(39):64300-64308. PubMed ID: 27588404
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract][Full Text] [Related]
12. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.
Masugi Y; Nishihara R; Yang J; Mima K; da Silva A; Shi Y; Inamura K; Cao Y; Song M; Nowak JA; Liao X; Nosho K; Chan AT; Giannakis M; Bass AJ; Hodi FS; Freeman GJ; Rodig S; Fuchs CS; Qian ZR; Ogino S
Gut; 2017 Aug; 66(8):1463-1473. PubMed ID: 27196573
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.
Hecht M; Büttner-Herold M; Erlenbach-Wünsch K; Haderlein M; Croner R; Grützmann R; Hartmann A; Fietkau R; Distel LV
Eur J Cancer; 2016 Sep; 65():52-60. PubMed ID: 27468145
[TBL] [Abstract][Full Text] [Related]
15. The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.
Chen MF; Chen PT; Chen WC; Lu MS; Lin PY; Lee KD
Oncotarget; 2016 Feb; 7(7):7913-24. PubMed ID: 26761210
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
Zhang J; Fang W; Qin T; Yang Y; Hong S; Liang W; Ma Y; Zhao H; Huang Y; Xue C; Huang P; Hu Z; Zhao Y; Zhang L
Med Oncol; 2015 Mar; 32(3):86. PubMed ID: 25702326
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.
Cimino-Mathews A; Thompson E; Taube JM; Ye X; Lu Y; Meeker A; Xu H; Sharma R; Lecksell K; Cornish TC; Cuka N; Argani P; Emens LA
Hum Pathol; 2016 Jan; 47(1):52-63. PubMed ID: 26527522
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
19. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.
Gabrielson A; Wu Y; Wang H; Jiang J; Kallakury B; Gatalica Z; Reddy S; Kleiner D; Fishbein T; Johnson L; Island E; Satoskar R; Banovac F; Jha R; Kachhela J; Feng P; Zhang T; Tesfaye A; Prins P; Loffredo C; Marshall J; Weiner L; Atkins M; He AR
Cancer Immunol Res; 2016 May; 4(5):419-30. PubMed ID: 26968206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]